We initially utilized real‐time PCR and immunoblotting to confirm that METTL3 KD can remarkably decrease the expression of histone modifiers in both TMZ‐resistant (Figure 5D and E) and ‐sensitive GBM cells (Figure S5B and S5C). This evidence concerns the gene METTL3 and glioblastoma.